Home > Analytics > MANKIND PHARMA

MANKIND PHARMA
Intrinsic Value | Fundamental Analysis

BOM : 543904     NSE : MANKIND    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward
Pledged Shares : NA
Oct 07,2024
Price(EOD): ₹ 2,558.55
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 102,495.51 Cr
Value of ₹ 1 Lac invested in MANKIND PHARMA
on May 09,2023 (price: ₹ 1,424.05)

₹ 1 L

₹ 1.80 L

1W : 1.5% 1M : 3.6% 1Y : 45%
COMMUNITY POLL
for MANKIND PHARMA
Please provide your vote to see the results
MANKIND PHARMA is part of below Screeners ↓
Top Large Cap Stocks with Best Fundamentals
Best Quarterly Growth Large Cap Stocks
Industry Peers & Returns1W1M1Y
MANKIND PHARMA 1.5% 3.6% 45%
SUN PHARMACEUTICAL INDUSTRIES -1.1% 4.4% 67.3%
CIPLA -1.8% -0.2% 37.2%
DR REDDYS LABORATORIES -2.3% -1.4% 21.5%
ZYDUS LIFESCIENCES -1.6% -5.8% 73.2%
DIVIS LABORATORIES -0.8% 5.4% 45.7%

FUNDAMENTAL ANALYSIS OF MANKIND PHARMA

 
Fundamentals Score
[ Q(TTM): Jun2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 MANKIND is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF MANKIND PHARMA

 
Valuation Score
[As on : Oct 07,2024 ]

Ratio Consolidated
P/E
P/B
P/S
51.87
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,976.25 Cr
[Latest Qtr - Jun2024 - Consolidated Results ]

10.98
P/B Calculated based on Book Value of Rs 9,339.84 Cr
[Latest Year - Mar2024 - Consolidated Results ]

9.63
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 10,649.60 Cr
[Latest Qtr - Jun2024 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 9% undervalued companies ! Discover More →

FAIR VALUE OF MANKIND PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
13021%
11828%
-

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF MANKIND PHARMA



MANKIND PHARMA vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF MANKIND PHARMA

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0
0
0.1
0.03
0.02
0.02
0.14
0.06
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF MANKIND PHARMA

Pledged Promoter Shares
NA

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF MANKIND PHARMA

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
18.53%
15.34%
16.61%
13.7%
12.21%
4.12%
7.09%
10.15%
QtrlyTrend
8
Latest Qtr: Jun2024
Quarterly Result Analysis →


MANKIND PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE -3% -0.7% 51.3%
S&P BSE 500 -5.4% -2.5% 33.4%
S&P BSE ALLCAP -5.4% -2.6% 34.2%
S&P BSE LARGE MIDCAP -5.4% -2.4% 32.2%
S&P BSE 200 -5.4% -2.2% 32.5%
NSE Indices1W1M1Y
NIFTY PHARMA -2.3% -0.9% 49%
NIFTY MID SMALL400 -4.9% -3.4% 41.4%
NIFTY MIDCAP150 -4.9% -2.9% 40.4%
NIFTY FREE MIDCAP 100 -5.1% -3.3% 41.4%
NIFTY500 MULTICAP 50:25:25 -5.2% -2.8% 36.7%

You may also like the below Video Courses


FAQ about MANKIND PHARMA


Is MANKIND PHARMA good for long term investment?

As on Oct 07,2024, the Fundamentals of MANKIND PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of MANKIND PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is MANKIND PHARMA UnderValued or OverValued?

As on Oct 07,2024, MANKIND PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of MANKIND PHARMA ?

As on Oct 07,2024, the Intrinsic Value of MANKIND PHARMA is Rs. 20.47 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 19.50
Fair Value [Median EV / Sales Model] : Rs. 21.45
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of MANKIND PHARMA : Rs. 20.47

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is MANKIND PHARMA trading at a Premium or Discount?

As on Oct 07,2024, MANKIND PHARMA is trading at a Premium of 12396% based on the estimates of Median Intrinsic Value!